Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Histone deacetylation as a target for radiosensitization.

David Cerna1, Kevin Camphausen, Philip J Tofilon

  • 1Molecular Radiation Therapeutics Branch, National Cancer Institute, Bethesda Maryland 20892, USA.

Current Topics in Developmental Biology
|June 20, 2006
PubMed
Summary

Histone deacetylase (HDAC) inhibitors enhance tumor radiosensitivity by potentially inhibiting DNA repair. These compounds show promise in improving radiotherapy effectiveness for various solid tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiosensitization of Glioblastoma by the K-ras Inhibitor RMC-6236.

bioRxiv : the preprint server for biology·2026
Same author

CPSM: an R package for cancer patient survival risk model using transcriptomics and clinical data.

GigaScience·2026
Same author

Temporal Integration of Serum Proteomics, Metabolomics and MRI Tumor Volumetrics via Deep Learning Identifies Systemic Mediators of Glioblastoma Response to Chemoradiotherapy.

Research square·2026
Same author

A Phase 1 Dose-Escalation Trial of Reirradiation for Patients With Recurrent Glioblastoma.

Practical radiation oncology·2026
Same author

Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response After Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma.

medRxiv : the preprint server for health sciences·2026
Same author

The Proteasome Is Revealed as a Therapeutic Target in Recurrent Glioblastoma Xenografts.

Molecular cancer therapeutics·2026

Area of Science:

  • Molecular radiobiology
  • Cancer research
  • Epigenetics

Background:

  • Cellular radioresponse is regulated by molecular processes.
  • Histone acetylation, controlled by HATs and HDACs, influences chromatin structure and gene expression, impacting radioresponse.
  • HDAC activity is often aberrant in tumor cells, making HDACs a target for cancer therapy.

Purpose of the Study:

  • To investigate the role of histone deacetylase (HDAC) inhibitors in enhancing tumor radiosensitivity.
  • To explore the potential of HDAC inhibitors as adjuncts to radiotherapy.

Main Methods:

  • Development and testing of structurally diverse HDAC inhibitors.
  • Evaluation of HDAC inhibitor effects on in vitro radiosensitivity of human tumor cell lines.
  • Assessment of HDAC inhibitor effects on the radiosensitivity of human tumor xenografts.

Related Experiment Videos

Main Results:

  • HDAC inhibitors were shown to enhance the in vitro radiosensitivity of various human solid tumor cell lines.
  • HDAC inhibitors increased the radiosensitivity of human tumor xenografts.
  • Data suggest that HDAC inhibitors may enhance radiosensitivity by interfering with the repair of radiation-induced DNA damage.

Conclusions:

  • HDAC inhibitors represent a promising strategy for enhancing tumor radiosensitivity.
  • These compounds may improve the efficacy of radiotherapy when used in combination with radiation treatment.
  • HDAC inhibitors are currently in clinical trials for cancer treatment and show potential in combination with radiotherapy.